The detectability of ketamine and its metabolites in drug screenings is contingent upon several factors, including the type of test administered, the dosage used, and individual metabolism. Standard drug tests are not typically designed to detect ketamine. Specialized assays are required for its identification due to its distinct chemical structure and rapid metabolism. For example, a standard 5-panel drug screen generally screens for substances like amphetamines, cocaine, opiates, PCP, and THC, but not ketamine.
The necessity for specific testing arises from ketamine’s legitimate medical uses, including anesthesia and treatment-resistant depression. Widespread, untargeted screening would likely produce false positives due to cross-reactivity with other substances or lead to unwarranted scrutiny of individuals legitimately prescribed the medication. Therefore, focused testing is typically reserved for situations where there’s a specific clinical or forensic reason to suspect its use. Historically, ketamine testing has been more common in contexts such as forensic toxicology or drug-facilitated sexual assault investigations, rather than routine workplace drug screening.
